Chemokines and Atherosclerotic Plaque Progression: Towards Therapeutic Targeting?
From: Department of Cardiology, Leiden University Medical Centre, 2333 ZA, Leiden, The Netherlands. a.o.kraaijeveld@lacdr.leidenuniv.nl
Current pharmaceutical design
- Publish Date: 2007
- ISSN: 1873-4286
- Volume: 13
- Issue: 10
- Pages: 1039-52
- Medium: Internet
- Language: English
- Citation (JAMA): Kraaijeveld A O, de Jager S C A, van Berkel T J C, et al. Chemokines and Atherosclerotic Plaque Progression: Towards Therapeutic Targeting?. Curr. Pharm. Des. 2007;13:1039-52
Abstract
Atherosclerosis is currently viewed as an inflammatory disease in which the initiation and progression of the atherosclerotic plaque towards a rupture prone, unstable plaque is driven by leukocyte recruitment mediated by various inflammatory mediators. Recently, interest in chemotactic cytokines or chemokines with regard to atherosclerosis has been growing as chemokines mediate the influx of leukocytes that is typical of atherothrombosis. The activity of the majority of chemokines is overlapping and chemokines are not only produced by the various cellular constituents of the atherosclerotic plaque but also by activated platelets. Consequently, the direct influence of individual chemokines on plaque destabilisation and rupture is widespread and rather unclear. Experimental research has already established the role of a number of chemokines in advanced atherosclerosis. Nevertheless, given the complexity and size of the chemokine family, further screening of cardiovascular disease for chemokine level and genetic polymorphisms for chemokines will be warranted as the search for viable biomarkers of plaque destabilization as well as novel therapeutic targets for specific atheroregressive therapeutic compounds is ongoing. With regard to the latter, clinical trials with specific chemokine inhibitory strategies, like chemokine receptor antagonists, are already underway in other inflammatory disorders. Summarizing, chemokine inhibition likely constitutes an important therapeutic option next to already established drugs in the management of cardiovascular disease.
Mesh Headings (Keywords): Animals, Atherosclerosis, Biological Markers, Cardiovascular Agents, Cardiovascular Diseases, Chemokines, Disease Progression, Drug Design, Humans, Receptors, Chemokine, Rupture, Spontaneous
Check for Full Text / PubMed Unique Identifier (PMID): 17430167
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.